The Influence of the Primary Tumor on the Long-term Results of Pulmonary Metastasectomy for Metastatic Renal Cell Carcinoma

Abstract

Objective To investigate one of the primary tumor (PT) on pulmonary metastasectomy (PM) for metastatic renal cell carcinoma (RCC) and to define prognostic factors.

Methods Retrospective review of patients with pulmonary metastases from RCC from January 1999 through December 2008 was performed. All patients underwent PM with curative intend. TNM-classification, tumor stage and PT grade, disease-free-interval (DFI) from nephrectomy to the diagnosis of metastasis, systemic chemotherapy before surgical intervention, surgical procedures, morbidity, mortality, and survival were investigated.

Results One-hundred seven consecutive patients (age 61.5 ± 9.6 years) underwent PM. Morbidity and mortality rates were 15.0 and 0.9%, respectively. Thirty-six patients (33.6%) had systematic therapy before PM. Complete resections could be achieved in 104 patients (97.2%). Mean survival was 63.4 ± 5.1 months. The overall 5- and 10-year survival rates were 47 and 9%, respectively. Advanced N-Status (p < 0.001), grade (p < 0.001) and stage group (stage I/II vs. III/IV, p = 0.022) of the PT were associated with inferior survival in the univariate analysis. T-Status (p = 0.89) and M-Status (p = 0.96) of the PT had no significant impact on survival. In a multivariable Cox proportional hazards model, N-Status and tumor grade were the only significant prognostic factors.

Conclusions PM can be performed safely. Long-term survival is achievable in selected patients. Nodal disease and high tumor grade of the PT at the time of the initial nephrectomy were associated with worse survival after PM. These results might help to identify a high-risk group of patients who might benefit from enrollment in adjuvant therapy protocols after primary treatment of RCC.

Keywords

renal cell carcinoma - pulmonary metastasectomy - nephrectomy - prognostic factor

• References

• 1 Jemal A, Siegel R, Ward E , et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56 (2) 106-130
• 2 Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335 (12) 865-875
• 3 Motzer RJ, Hutson TE, Tomczak P , et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356 (2) 115-124
• 4 Dernevik L, Berggren H, Larsson S, Roberts D. Surgical removal of pulmonary metastases from renal cell carcinoma. Scand J Urol Nephrol 1985; 19 (2) 133-137
• 5 Pogrebniak HW, Haas G, Linehan WM, Rosenberg SA, Pass HI. Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 1992; 54 (1) 33-38
• 6 Sobin LH, Wittekind C . TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002
• 7 Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6 (7) 655-663
• 8 Vogt-Moykopf I, Krysa S, Bülzebruck H, Schirren J. Surgery for pulmonary metastases. The Heidelberg experience. Chest Surg Clin N Am 1994; 4 (1) 85-112
• 9 Schirren J, Bergmann T, Beqiri S, Bölükbas S, Fisseler-Eckhoff A, Vogt-Moykopf I. Lymphatic spread in resectable lung cancer: can we trust in a sentinel lymph node?. Thorac Cardiovasc Surg 2006; 54 (6) 373-380
• 10 Therasse P, Arbuck SG, Eisenhauer EA , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (3) 205-216
• 11 Leibovich BC, Cheville JC, Lohse CM , et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174 (5) 1759-1763, discussion 1763
• 12 Clark JI, Atkins MB, Urba WJ , et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21 (16) 3133-3140
• 13 Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol 2006; 33 (5) 576-582
• 14 Volkmer BG, Gschwend JE. [Value of metastases surgery in metastatic renal cell carcinoma]. Urologe A 2002; 41 (3) 225-230
• 15 Marulli G, Sartori F, Bassi PF, dal Moro F, Gino Favaretto A, Rea F. Long-term results of surgical management of pulmonary metastases from renal cell carcinoma. Thorac Cardiovasc Surg 2006; 54 (8) 544-547
• 16 Assouad J, Petkova B, Berna P, Dujon A, Foucault C, Riquet M. Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg 2007; 84 (4) 1114-1120
• 17 Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 2002; 74 (5) 1653-1657
• 18 Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 2005; 48 (1) 77-81, discussion 81–82
• 19 Pantuck AJ, Zisman A, Dorey F , et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003; 169 (6) 2076-2083
• 20 Pantuck AJ, Zisman A, Dorey F , et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003; 97 (12) 2995-3002
• 21 Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001; 166 (1) 68-72
• 22 Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clin North Am 2003; 30 (3) 467-480
• 23 Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163 (4) 1090-1095, quiz 1295
• 24 Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990; 143 (3) 468-473, discussion 473–474
• 25 Lohse CM, Cheville JC. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med 2005; 25 (2) 433-464